Will spinach reheat NUFA?
This article was originally published in The Tan Sheet
Executive Summary
Consumers Union cites the recent contamination of fresh spinach with E. coli bacteria as a reason to oppose passage of the National Uniformity for Food Act (S 3128). The bill, which would unify warning label requirements and preempt state-imposed requirements like California's Prop 65, passed the House in February with an amendment exempting warnings related to dietary supplements. No action has been taken on NUFA since a July Senate Health, Education, Labor & Pensions Committee hearing, and Consumers Union does not think the bill will be taken up during the lame-duck session. Congress "is not really doing much of a substantive nature between now and the new session," a spokesperson said (1"The Tan Sheet" July 31, 2006, In Brief). However, the group expects NUFA will be reintroduced into the new Congress and notes Speaker-designate Rep. Nancy Pelosi (D-Calif.) opposes the bill. Supplement trade groups have not heard rumblings on the Hill about new movement on the bill in light of the spinach contamination...
You may also be interested in...
NUFA hearing
The Senate Committee on Health, Education, Labor & Pensions held a hearing on the National Uniformity for Food Act (S 3128) July 27. Witnesses included Peter Barton Hutt, Senior Counsel for Covington & Burling (Washington, D.C.), and former FDA Associate Commissioner for Policy William Hubbard. The HELP committee does not expect to vote on the legislation until after the August recess. NUFA was introduced in the House in October 2005. After the bill (H.R. 4167) passed the House in late February, it was referred to the Senate. The companion bill was introduced by Sen. Richard Burr (R-N.C.) May 25...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.